Just After Pfizer's RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population
Just After Pfizer's RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population
On Thursday, GSK plc (NYSE:GSK) revealed new preliminary data for Arexvy (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 18-49 at increased risk for lower respiratory tract disease (LRTD).
紐交所（NYSE:GSK）週四公佈了Arexvy（呼吸道合胞病毒-疫苗，佐劑）在18-49歲增加下呼吸道疾病（LRTD）風險成年人中的新初步數據。
The data show that the vaccine has the potential to help protect a broader group of adults at risk from the potentially serious consequences of RSV.
數據顯示，這種疫苗有潛力幫助保護更廣泛的有風險的成年人，以免受呼吸道合胞病毒潛在嚴重後果的影響。
In the U.S. alone, the number of adults aged 18-49 with at least one risk factor that could put them at risk for RSV disease could exceed 21 million.
僅在美國，有至少一個風險因素的18-49歲成年人，可能有超過2100萬人面臨呼吸道合胞病毒疾病風險。
Also Read: GSK, Pfizer Face Declining Respiratory Syncytial Virus Vaccine Sales Due To Narrow Age Recommendations
還有文章：GSK、輝瑞因狹窄的年齡建議面臨呼吸道合胞病毒疫苗銷售下滑。
The vaccine is currently approved for active immunization to prevent RSV-LRTD in adults aged 60 and older and in adults aged 50-59 at increased risk.
目前該疫苗已獲批用於預防60歲及以上成年人和有增加風險的50-59歲成年人患RSV-LRTD。
There are currently no RSV vaccines recommended for adults younger than 60 years of age who are at increased risk for RSV disease.
目前沒有推薦給有RSV疾病風險的60歲以下成年人使用RSV疫苗。
In the phase 3b trial, a single dose of the vaccine elicited robust immune responses in adults aged 18-49 at increased risk for RSV-LRTD due to certain underlying medical conditions (n=395).
在30億階段試驗中，一劑疫苗在由於特定潛在醫療條件（n=395）導致18-49歲有RSV-LRTD風險成年人中引發了強有力的免疫反應。
The immune response was non-inferior to that observed in adults 60 and older (n=417), meeting the trial's co-primary endpoints.
免疫反應非劣於60歲及以上成年人（n=417），達到了試驗的共同主要終點。
In the phase 2b trial, a single dose of the vaccine showed a robust immune response in adults aged 18 and older who are immunocompromised due to kidney or lung transplant (n=131), with a second dose (n=130) eliciting responses similar to those of healthy adults aged 50 and older who received one dose (n=125).
在20億的試驗階段，疫苗的單劑接種在年齡在18歲及以上的免疫系統受損因腎臟或肺移植（n=131）成人中顯示出強大的免疫應答，第二劑（n=130）引發類似於接種單劑的年齡在50歲及以上的健康成人（n=125）的應答。
These immune responses were consistent for RSV-A and RSV-B subtypes in all groups (those who received 1 or 2 doses).
這些免疫應答在所有組中（接種1劑或2劑的人群）對RSV-A和RSV-b亞型保持一致。
Earlier this week, the FDA approved Pfizer Inc's (NYSE:PFE) Abrysvo (Respiratory Syncytial Virus Vaccine), the company's bivalent RSV prefusion F (RSVpreF) vaccine, to prevent lower respiratory tract disease (LRTD) caused by RSV in individuals 18 through 59 who are at high risk.
本週早些時候，FDA批准了輝瑞公司（紐交所:PFE）的Abrysvo（呼吸道合胞病毒疫苗），該公司的雙價RSV前融合F（RSVpreF）疫苗，用於預防18至59歲面臨高風險的個體由RSV引起的下呼吸道疾病（LRTD）。
In June, the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend the routine use of Respiratory Syncytial Virus (RSV) vaccines in all adults aged 75 and above.
六月份，美國疾病控制和預防中心（CDC）的免疫接種實踐諮詢委員會（ACIP）投票建議所有年齡在75歲及以上的成年人定期接種呼吸道合胞病毒（RSV）疫苗。
ACIP postponed a vote on a recommendation for adults aged 50-59 years at increased risk for RSV-LRTD until additional data became available.
ACIP推遲對於處於50至59歲且處於增高RSV-下呼吸道界定疾病風險的成人的免疫接種建議的表決，直到有更多數據可用。
Price Action: GSK stock is down 0.53% at $37.78 at the last check on Thursday.
股價走勢：GSK股票在週四最後一次檢查時下跌0.53%，報37.78美元。
- Verizon Faces Slower Growth, Declining Cash Flow In 2025, Analyst Downgrades Stock
- verizon面臨着2025年增速放緩、現金流下降的挑戰，分析師下調了股票評級。
譯文內容由第三人軟體翻譯。
